WALTHAM, Mass. - Repligen (NASDAQ:RGEN) Corporation (NASDAQ:RGEN), a global life sciences company, announced today the expansion of its Board of Directors with the appointment of Maggie A. Pax. The board now comprises nine members, with Ms. Pax bringing over two decades of experience in the life sciences sector.
Ms. Pax has an extensive background in strategic planning and innovation, notably during her tenure at Thermo Fisher Scientific (NYSE:TMO). As Vice President, Strategy and Innovation for Thermo Fisher's clinical supply chain business from 2016 to 2020, she spearheaded strategic initiatives and customer innovation programs. Her efforts were instrumental in Thermo Fisher's acquisition of Patheon, a key player in biopharmaceutical contract manufacturing.
Karen A. Dawes, Repligen's Board Chairperson, expressed confidence in Pax's alignment with the company's leadership and her proven expertise in driving strategic change and product innovation. CEO Tony J. Hunt also echoed the sentiment, highlighting Pax's understanding of growth drivers in the industry and her experience with key account programs, innovation, and mergers and acquisitions (M&A) integration.
Prior to her roles at Thermo Fisher, Ms. Pax held senior positions at Phillips Healthcare and was involved in entrepreneurial ventures, including a Vice President role at Microchips Biomedical. Currently, she serves on the boards of several healthcare and life sciences companies, including Alimera (NASDAQ:ALIM) Sciences and Jellagen, and advises on business strategy and growth.
Repligen is known for its development and commercialization of bioprocessing technologies and systems, which are crucial for the manufacturing of biological drugs. The company, headquartered in Waltham, Massachusetts, operates globally with manufacturing sites in the United States and Europe.
This announcement is based on a press release statement from Repligen Corporation. The company has cautioned that the press release may contain forward-looking statements subject to risks and uncertainties that could cause actual results to differ from those anticipated.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.